AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$AGMB

Kemula Pierre Thadee Victor purchased $86K of AGMB

Kemula Pierre Thadee Victor (Chief Financial Officer) purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.59 ($8.54–$8.67) across 3 trades on 2026-10-06.

Original reporting
SEC EDGAR · Kemula Pierre Thadee Victor
Published Oct 7, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AGMB
Neutral
high confidence
Mentioned
$AGMB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGMBNeutralLow
01

Why it matters

The CFO's purchase is a modest signal of confidence but unlikely to affect the stock materially.

02

Market read

Small insider buy provides a fresh data point but limited trading relevance.

03

What to watch

Potential upcoming clinical data could make the insider buy more meaningful if disclosed later.

Relevance 4/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$AGMBNeutralHigh confidence
Context

CFO Kemula Pierre Thadee Victor bought 10,000 shares of AGMB for $85,940 in a Form 4 filing.

Expected impact

modest buying pressure as the market absorbs the small insider buy

Evidence & confidence

First‑report Form 4, direct purchase by CFO, but only $86K total value; unlikely to move price significantly.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional impact.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The purchase may be routine compensation rather than a strong bullish signal.

Key entities

  • company
    AgomAb Therapeutics NV

    Biotech company listed on Nasdaq under ticker AGMB.

  • person
    Kemula Pierre Thadee Victor

    Chief Financial Officer of AGMB.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AGMB insider trading history →

Related articles

OCT 14
$AGMBMedAI 8/10

Agomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's Disease

AgomAb Therapeutics (AGMB) dosed the first patient in a Phase 2b trial of Ontunisertib for Crohn's disease. The trial aims to enroll 320 adults with symptomatic fibrostenosing Crohn's disease across multiple countries. Ontunisertib has FDA Fast Track Designation and showed positive results in an earlier Phase 2a trial. The study's primary endpoint is endoscopic passability of ileal strictures at Week 24.

rttnews.com2 min
OCT 13
$AGMBMedAI 8/10

Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease

Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.

tipranks.com1 min
OCT 8
LowAI 8/10

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.

globenewswire.com2 min
OCT 2
$AGMBMedAI 8/10

H.C. Wainwright reiterates Agomab stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.

investing.com2 min
OCT 1
$AGMBMedAI 8/10

Why is Agomab Therapeutics stock sliding today?

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

investing.com2 min
OCT 1
$AGMBHighAI 8/10

Agomab stock jumps on positive trial data

Agomab Therapeutics (NASDAQ:AGMB) shares rose 6.3% premarket after positive trial data for ontunisertib in Crohn's disease. The STENOVA extension study showed favorable safety, low event rates, and sustained disease control. 97% of patients were in remission at Week 48. The company plans a Phase 2b study. Ontunisertib has FDA Fast Track Designation.

investing.com2 min